Skip to main content

COVID-19 Vaccination in the UK: We Need a Sustainable Infrastructure for the Programme

 Earlier this week, we learned that more than 10 million people in the UK have now received their first dose of a COVID-19 vaccine, including 90% of people aged 75 and over. All residents of care homes have also now been offered a vaccination. This is excellent news and means that the groups that for the vast majority of COVID-19 deaths have now been immunised. 

We will start to see the effects of vaccination in the coming weeks once enough time has elapsed for people to develop post-vaccination immunity. In particular, this should result in a reduced burden on the NHS as well as a lower death rate. But although we can be proud about what the vaccination achieved, we also need to remember that the programme is a marathon and not a sprint. There is a lot more work to do yet to complete the programme.

As well as continuing to offer first doses of vaccine to people, in April we will need to start offering the delayed second doses of vaccine, which will substantially increase the workload generated by the vaccination programme and place greater demands on NHS vaccination teams. We have also thus far been vaccinating the groups where “vaccine hesitancy” is generally low, such as the elderly and health professionals. As the figure below shows, from the UK Office for National Staistics, we will now start to vaccinate younger people, among whom vaccine hesitancy is at a much higher level than among older people. 

Vaccine hestitancy is also more common in Black and other minority ethnic groups, as shown below, in a figure also from the UK Office for National Statistics. These groups are at higher risk of infection, severe disease and death. Hence, it is essential that vaccine hesitancy is also addressed in ethnic minority groups through sustained engagement with communities.

It’s also possible that people will need additional “booster” doses of vaccine at some point to counteract the effects of decreasing vaccine-generated immunity and to deal with new variants of SARS-CoV-2 amongst which current vaccines may be less effective. To help develop these modified vaccines, we will need continued research and it’s essential that members of the public sign up to take part in these projects; in particular, older people and people from ethnic minority groups, both of whom are often under-represented in trials. 

We have made great progress in developing vaccines and implementing a vaccination programme. Congratulations to all for this; including industry, universities, government, the NHS and the public. But we are only at the start of this programme. We will need a sustainable, long-term vaccine infrastructure that will require investment and staffing, as well as continuing to update our vaccines to deal with new variants of SARS-CoV-2 if current vaccines are not fully effective against them.


Comments

Post a Comment

Popular posts from this blog

Protecting Against the "Quad-demic": Influenza, Covid-19, Norovirus and RSV

As the NHS braces for a challenging winter season, it is grappling with a "quad-demic" of health emergencies caused by influenza, Covid-19, norovirus, and respiratory syncytial virus (RSV). This confluence of viral threats poses a significant risk to public health in the UK as well as putting strain on healthcare resources, emphasising the importance of preventive measures to safeguard public health. Public health measures such a vaccination and good personal hygiene are pivotal in reducing the impact of these illnesses, particularly for vulnerable groups. The Four Viruses: What Are They? Influenza: A highly contagious respiratory infection that causes significant illness each winter. It can lead to severe complications, particularly in the elderly, young children, pregnant women, and those with chronic health conditions. Covid-19: Though its most acute phase has passed, Covid-19 remains a concern, especially as new variants of SA...
Post a Comment
Read more

MPH Student Presentations on the NHS Care.Data Programme

As part of a session on primary care data in the Health Informatics module on the Imperial Master of Public Health Programme, I asked students to work in two groups to present arguments for and against the NHS Care.Data programme. Care.Data is an NHS programme that will extract data from the medical records held by general practitioners (GPs) in England. The Care.Data programme takes advantage of the very high level of use of electronic medical records by GPs in England. After extraction, data will be uploaded to the NHS Health and Social Care Information Centre (HSCIC). The data will then be used for functions such as health care planning, monitoring disease patterns and research. The programme has been controversial with proponents arguing that the programme will bring many benefits for the NHS and the population of England; and opponents arguing it is a major breach of privacy. You can view the two presentations to help inform you further about these arguments: Arguments fo...
6 comments
Read more

How can we work successfully across the health and care system to make a success of Pharmacy First?

Pharmacies in England to begin treating patients for seven common conditions. How can we work successfully across the health and care system to make a success of Pharmacy First? 1. The Pharmacy First scheme aims to provide convenient access to healthcare through community pharmacies. Patients with minor ailments or common conditions can seek advice and treatment directly from their local pharmacy instead of visiting a general practice, urgent care centre or emergency department. The conditions covered by the scheme may vary depending on local funding arrangements and participation of pharmacies.  2, A potential problem with Pharmacy First is pharmacists misdiagnosing a patient's condition. It may also lead to delays in patients seeing doctors when medical assessment is needed. To mitigate these risks, appropriate safeguards and referral pathways should be established, ensuring timely medical assessment when necessary. The scheme will also increase the workload of pharmacies, thereb...
Post a Comment
Read more